Is CRVS or CTMX more undervalued in 2026?

CirclFi compares Corvus Pharmaceuticals, Inc. (CRVS) and CytomX Therapeutics, Inc. (CTMX) using 13 institutional-grade valuation models. CRVS has a Quality of Company score of 4.6/10 while CTMX scores 6.7/10.

Which is a better buy — CRVS or CTMX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRVS and CTMX valuations compare?

CRVS at $12.50 and CTMX at $3.71 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRVS vs CTMX Valuation Comparison 2026 — Intrinsic Value Analysis

CRVS

Biotechnology

Corvus Pharmaceuticals, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$12.50

Last close

Models

7/13

Active

CTMX

Biotechnology

CytomX Therapeutics, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$3.71

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CRVS Fair Value	CRVS Upside	CTMX Fair Value	CTMX Upside
Bayesian DCF	Intrinsic	$3.61	-71.1%	$0.80	-78.4%
Earnings Power Value	Intrinsic	—	—	$0.37	-90.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.51	-96.7%	$0.29	-92.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRVS vs CTMX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRVS vs CTMX — Which Stock Is More Undervalued?

CTMX scores higher with a 6.7/10 quality rating vs CRVS's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Corvus Pharmaceuticals, Inc. (CRVS) and CytomX Therapeutics, Inc. (CTMX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRVS currently trades at $12.50 with a QOC of 4.6/10, while CTMX trades at $3.71 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).